{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:42:28Z","timestamp":1777934548643,"version":"3.51.4"},"reference-count":19,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2021,11,9]],"date-time":"2021-11-09T00:00:00Z","timestamp":1636416000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Palbociclib is a small-molecule cyclin-dependent kinase 4\/6 inhibitor used to treat hormone receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer. Patient-specific factors impacting dose reductions or discontinuations are unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The primary objective was to evaluate the association of age (&lt;60 vs. \u226560 years) with palbociclib dose reductions or discontinuations secondary to neutropenia. This single-center, retrospective chart review included hormone receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer patients \u226518 years treated with palbociclib between April 2015 and May 2020. Patients &lt;60 years at the time of palbociclib initiation were in the younger group and patients \u226560 years were in the older group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among the 107 patients included, younger patients were less likely than older patients to have a palbociclib starting dose &lt;125\u2005mg (0% vs. 11.9%, p\u2009=\u20090.02). Differences in palbociclib dose reductions or treatment discontinuations secondary to neutropenia were not detected (35.4% vs. 42.4%, p\u2009=\u20090.55). Neither the total number of palbociclib dose reductions (none: 54.2% vs. 49.1%, one: 33.3% vs. 42.4%, two: 12.5% vs. 8.5%, p\u2009=\u20090.61), nor the final dose of palbociclib (125 mg: 54.2% vs. 40.7%, 100 mg: 29.2% vs. 27.1%, 75 mg: 16.7% vs. 32.2%, p\u2009=\u20090.17) differed between younger and older patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Age (&lt;60 vs. \u226560 years) was not associated with the rate of palbociclib dose reductions or discontinuations secondary to neutropenia. Older (\u226560 years) patients were more likely to start palbociclib at lower doses which may impact neutropenia and non-neutropenic intolerance.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552211053639","type":"journal-article","created":{"date-parts":[[2021,11,9]],"date-time":"2021-11-09T07:00:22Z","timestamp":1636441222000},"page":"96-104","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":7,"title":["Tolerability of palbociclib in younger and older patients with advanced breast cancer"],"prefix":"10.1177","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9582-2688","authenticated-orcid":false,"given":"Taylor","family":"Dennison","sequence":"first","affiliation":[{"name":"Department of Pharmacy, University of North Carolina Medical Center, Chapel Hill, NC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hillary","family":"Heiling","sequence":"additional","affiliation":[{"name":"University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allison","family":"Deal","sequence":"additional","affiliation":[{"name":"University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly","family":"Brunk","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Kansas Cancer Center, Kansas, KS, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5468-7827","authenticated-orcid":false,"given":"Ryan","family":"Kemper","sequence":"additional","affiliation":[{"name":"Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel J","family":"Crona","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of North Carolina Medical Center, Chapel Hill, NC, USA"},{"name":"University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA"},{"name":"Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aimee","family":"Faso","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of North Carolina Medical Center, Chapel Hill, NC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2021,11,9]]},"reference":[{"key":"bibr1-10781552211053639","unstructured":"Ibrance (Palbociclib). [package insert]. New York, NY: Pfizer Labs; September 2019."},{"key":"bibr2-10781552211053639","unstructured":"Breast Cancer. Version 1.2021. National Comprehensive Cancer Network, https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breastpdf (accessed 13 April 2021)."},{"key":"bibr3-10781552211053639","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-019-0769-3"},{"key":"bibr4-10781552211053639","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71159-3"},{"key":"bibr5-10781552211053639","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607303"},{"key":"bibr6-10781552211053639","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1810527"},{"key":"bibr7-10781552211053639","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JGO.19.11000","volume":"5","author":"Im SA","year":"2019","journal-title":"J Glob Oncol"},{"key":"bibr8-10781552211053639","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609709"},{"key":"bibr9-10781552211053639","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.6155"},{"key":"bibr10-10781552211053639","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1421"},{"key":"bibr11-10781552211053639","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0142"},{"key":"bibr12-10781552211053639","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"bibr13-10781552211053639","doi-asserted-by":"publisher","DOI":"10.7573\/dic.212579"},{"key":"bibr14-10781552211053639","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505270"},{"key":"bibr15-10781552211053639","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-017-4606-9"},{"key":"bibr16-10781552211053639","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.27832"},{"key":"bibr17-10781552211053639","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.05.017"},{"key":"bibr18-10781552211053639","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-018-0958-2"},{"key":"bibr19-10781552211053639","first-page":"1","volume":"13","author":"Bui TV","year":"2019","journal-title":"Breast Cancer"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552211053639","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552211053639","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552211053639","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:25:41Z","timestamp":1777688741000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552211053639"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,9]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["10.1177\/10781552211053639"],"URL":"https:\/\/doi.org\/10.1177\/10781552211053639","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,9]]}}}